Autobio Diagnostics (603658.SS) Earnings Analysis
Autobio Diagnostics (603658.SS) next reports earnings on 2026-08-25. Last quarter (2026-04-23) it missed with EPS 0.36 CNY vs 0.7 CNY est (-48.6%). It has beaten estimates in 1/6 recent quarters (17%). Trailing P/E 17.88.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does 603658.SS next report earnings?
| Next earnings date | 2026-08-25 |
|---|---|
| Consensus EPS estimate | n/a |
| Revenue estimate | 0.98B |
603658.SS earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-04-23 | 0.36 CNY | 0.7 CNY | -48.6% | Miss |
| 2026-04-22 | 0.41 CNY | n/a | n/a | n/a |
| 2025-10-29 | 0.505 CNY | 0.7 CNY | -27.9% | Miss |
| 2025-08-21 | 0.53 CNY | 0.57 CNY | -7% | Miss |
| 2025-04-17 | 0.42 CNY | 0.6 CNY | -30% | Miss |
| 2024-10-25 | 0.56 CNY | 0.66 CNY | -15.2% | Miss |
| 2024-08-20 | 0.53 CNY | 0.5 CNY | +6% | Beat |
Beat rate: 1/6 (17%) over reported quarters with consensus data.
603658.SS valuation and analyst view
| Trailing P/E | 17.88 |
|---|---|
| Trailing EPS | 1.811 CNY |
| Price / book | 2.01 |
| Dividend yield | 4.07% |
| Market cap | 18.70B |
Limited or no published sell-side analyst coverage for this symbol.
Related research pages
Frequently asked questions
When is Autobio Diagnostics (603658.SS)'s next earnings date?
Autobio Diagnostics is next scheduled to report on 2026-08-25 and revenue estimate of 0.98B.
Did 603658.SS beat earnings last quarter?
In its 2026-04-23 report, 603658.SS posted EPS of 0.36 CNY versus a 0.7 CNY estimate — a miss of 48.6%.
What is 603658.SS's earnings track record?
Over the last 6 reported quarters with consensus data, 603658.SS beat estimates 1 times (17%).
What is 603658.SS's current P/E ratio and EPS?
603658.SS trades at a trailing P/E of 17.88 on trailing EPS of 1.8105333421599255 CNY.
What do analysts rate 603658.SS?
603658.SS has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.